Critical

Neonatal herpes simplex virus (HSV) infection

Treat empirically, low threshold · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Neonatal HSV presents as skin-eye-mouth (SEM), CNS, or disseminated disease, usually within the first 4 weeks of life, and can be rapidly fatal with high-dose IV aciclovir the cornerstone. Because mortality and neurodisability rise with any delay and many mothers are asymptomatic, treat empirically on suspicion while awaiting confirmation.

Red flags

  • Seizures, encephalopathy or bulging fontanelle
  • Vesicular rash (may be absent in up to a third)
  • Coagulopathy, deranged LFTs or shock (disseminated disease)
  • Maternal genital HSV (especially primary infection near delivery)
  • Any deterioration while on antibiotics alone

Assessment

Differential diagnosis

  • Bacterial early/late-onset sepsis
  • Enteroviral/parechovirus sepsis
  • Other congenital (TORCH) infection
  • Metabolic/inborn error with encephalopathy
  • Non-infective causes of neonatal seizures/hepatitis

Investigations

  • HSV PCR from blood, CSF, and surface swabs (skin vesicles, eyes, mouth, nasopharynx, rectum)
  • Lumbar puncture: CSF HSV PCR, cell count, protein, glucose
  • LFTs and coagulation (disseminated disease causes hepatitis/coagulopathy)
  • FBC, CRP, blood culture and full bacterial sepsis screen
  • EEG and cranial MRI for CNS disease
  • Ophthalmology review for keratoconjunctivitis

Management

  • Have a low threshold — consider HSV in any unwell neonate with sepsis, seizures, hepatitis, coagulopathy or vesicles
  • Start high-dose IV aciclovir empirically without waiting for PCR results
  • Take HSV PCR from blood, CSF and all surface sites, plus LFTs and coagulation, before/at starting treatment
  • Perform a lumbar puncture unless clinically contraindicated
  • Continue broad-spectrum antibiotics until bacterial sepsis excluded
  • Support organ dysfunction — correct coagulopathy, manage seizures and liver failure
  • Treat SEM disease for 14 days and CNS/disseminated disease for a minimum of 21 days IV
  • Repeat CSF HSV PCR near the end of treatment in CNS disease — continue aciclovir until PCR negative
  • Ensure adequate hydration and monitor renal function (aciclovir nephrotoxicity)
  • On completing IV therapy, start oral aciclovir suppression for 6 months to improve neurodevelopmental outcome

Drugs & doses

Aciclovir 20 mg/kg/dose IV every 8 hours (14 days SEM; >=21 days CNS/disseminated)
Oral aciclovir suppression 300 mg/m2/dose three times daily for 6 months after IV course
Benzylpenicillin + gentamicin empirically until bacterial sepsis excluded
Ensure IV hydration; adjust aciclovir dosing interval for renal impairment

Disposition

Admit to NICU with infectious diseases input; IV aciclovir and supportive care. Neurodevelopmental, ophthalmology and audiology follow-up after discharge.

Complications & pitfalls

  • Death (high in untreated disseminated disease)
  • Severe neurodevelopmental impairment and epilepsy
  • Recurrent skin/eye disease
  • Liver failure and DIC
  • Aciclovir-related neutropenia/nephrotoxicity

Exam pearls

  • Absence of a rash and absence of maternal history do NOT exclude neonatal HSV
  • Start aciclovir empirically — do not wait for PCR in a sick neonate
  • Confirm CSF HSV PCR negativity at end of CNS treatment before stopping IV aciclovir
  • Six months of oral suppression improves neurodevelopmental outcomes after CNS disease

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.